STO-609 |
| Catalog No.GC37694 |
STO-609 is a selective and cell-permeable inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 52029-86-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
STO-609 is a selective and cell-permeable inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively[1]. CaM-KK is a key signal transduction protein that plays an important role in intracellular calcium signal transduction by activating members of the CaM kinase family (such as CaM-KI, CaM-KIV, etc.)[2]. STO-609 is typically used to study CAM-KK-related signaling pathways and their roles in various cellular physiological processes such as cell proliferation, differentiation, metabolism, and neural signal transduction[3][4].
In vitro, treatment of non-functional pituitary adenoma (NFPA) cells with STO-609 (0.4-51.2μM; 24h)significantly inhibits cells proliferation and migration and induces apoptosis in a dose-dependent manner by suppressing the Ca²⁺/CaM signaling pathway[5]. Treatment of insect neurosecretory cells with STO-609 (15μM; 10min) significantly reduced nicotine-induced currents and intracellular calcium levels increase by inhibiting the CaMKK/AMPK pathway[6].
In vivo, STO-609 (30μg/kg; i.p.; twice a week; 3 weeks) significantly reduced the lung weight of mice inhibited experimental lung metastasis in mice with oral squamous cell carcinoma (OSCC) cells overexpressing EP4[7].
References:
[1] Tokumitsu H, Inuzuka H, Ishikawa Y, Ikeda M, Saji I, Kobayashi R. STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002;277(18):15813-15818.
[2] Tokumitsu H, Sakagami H. Molecular Mechanisms Underlying Ca2+/Calmodulin-Dependent Protein Kinase Kinase Signal Transduction. Int J Mol Sci. 2022;23(19):11025.
[3] York B, Li F, Lin F, et al. Pharmacological inhibition of CaMKK2 with the selective antagonist STO-609 regresses NAFLD. Sci Rep. 2017;7(1):11793.
[4] Fujiwara Y, Hiraoka Y, Fujimoto T, Kanayama N, Magari M, Tokumitsu H. Analysis of Distinct Roles of CaMKK Isoforms Using STO-609-Resistant Mutants in Living Cells. Biochemistry. 2015;54(25):3969-3977.
[5] Wu B, Jiang S, Wang X, et al. Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609. PLoS One. 2020;15(10):e0240230.
[6] Taha M, Houchat JN, Taillebois E, Thany SH. The calcium-calmodulin-dependent protein kinase kinase inhibitor, STO-609, inhibits nicotine-induced currents and intracellular calcium increase in insect neurosecretory cells. J Neurochem. 2024;168(7):1281-1296.
[7] Ishikawa S, Umemura M, Nakakaji R, et al. EP4-induced mitochondrial localization and cell migration mediated by CALML6 in human oral squamous cell carcinoma. Commun Biol. 2024;7(1):567.
| Cell experiment [1]: | |
Cell lines | HP75 cells |
Preparation Method | HP75 cells were cultured in DMEM containing 15% horse serum, and 2.5% fetal calf serum at 37˚C in an easeful air atmosphere containing 5% carbon dioxide. The cells were seeded into 96-well plates for overnight, and the density is 1.0×105 cells/well. After washing culture medium, different doses of STO-609 were used to the cells and cultured for 24h, control group and solvent control group were classed by using normal saline (NS) and DMSO respectively, and 6 wells were prepared for doses of STO-609 (concentration gradients were 0.4μmol/L, 0.8μmol/L, 1.6μmol/L, 3.2μmol/L, 6.4μmol/L, 12.8μmol/L, 25.6μmol/L and 51.2μmol/L). Cells were cultured for 1h after added CCK-8 into wells with a quantity of 10μl/well. The wave length of 450nm was applied to measure OD value of each well on the microplate reader. |
Reaction Conditions | 0.4-51.2μM; 24h |
Applications | STO-609 significantly inhibits cells proliferation and migration and induces apoptosis in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | BALB/c Slc-nu/nu mice |
Preparation Method | HSC-3 cells transfected with the lentiviral scramble control or EP4 over expression were harvested and injected (2×106cells/0.2mL) into the tail veins of BALB/c Slc-nu/nu mice (female, 4–5 weeks old, 4 mice/group) (SLC). Each group of mice was administered either vehicle (0.1% dimethylsulfoxide in phosphate-buffered saline) or STO-609 by intraperitoneal injection (30μg/kg/body weight) twice per week for 3 weeks. Three weeks after the injection of the cells, the lungs were fixed with formalin, and the weights were measured. |
Dosage form | 30μg/kg; i.p.; twice per week; 3 weeks |
Applications | STO-609 significantly reduced the lung weight of mice. |
References: | |
| Cas No. | 52029-86-4 | SDF | |
| Canonical SMILES | O=C(C1=C2C3=C(C4=NC5=CC=CC=C5N4C(C3=CC=C2)=O)C=C1)O | ||
| Formula | C19H10N2O3 | M.Wt | 314.29 |
| Solubility | DMSO: 5.6 mg/mL (17.82 mM and warming); Water: < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1818 mL | 15.9089 mL | 31.8177 mL |
| 5 mM | 636.4 μL | 3.1818 mL | 6.3635 mL |
| 10 mM | 318.2 μL | 1.5909 mL | 3.1818 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *